A clinical and pharmacological study of XXXX , @entity4181 and interferon alfa in advanced @entity14 .

@entity4181 @entity1 @entity137 @entity5 @entity14 @entity1487
Modulation of @entity1487 (FUra) using @entity4181 (LV) is a standard treatment approach in @entity1 with metastatic @entity14 . Modulation of FUra with interferon alfa has also shown some promise. Laboratory data have demonstrated @entity137 when FUra is combined with both LV and interferon. The current study examined the effects of double modulation of FUra using LV and interferon. @entity1 with measurable advanced @entity14 received bolus FUra 375 mg/m2 plus LV 20 mg/m2 daily for 5 days, repeated every 28 days. Recombinant @entity1 interferon alfa-2a, 3 million IU/m2 subcutaneously, was given daily on the days of chemotherapy then three times weekly. There was one complete response and nine partial responses (10/41) seen for an overall response rate of 24% (95% CI 12.0-40.0%). Overall, 70% of @entity1 experienced one or more episodes of nonhematologic @entity137 of grade 3 or more. Weight loss was common, with a mean decrease of 2.9 kg over the first two months (P < 0.0001). Improvements in @entity5 -related symptoms were balanced by increased fatigue and a deterioration in body weight and performance status. There was no evidence of progressive changes in FUra metabolism from interferon usage.
